Diagnostics company AdvanDx is getting a $12 million infusion from the Merck Global Health Innovation Fund to expand its product offerings and sales and marketing efforts in the U.S. and abroad.
InfoBionic raised $17 million in Series B financing to develop its innovative patient monitoring system for cardiac arrhythmia.
Seattle-based Adaptive Biotechnologies announced April 7 that it has completed two rounds of financing, netting the company $120 million that it will use to expand sales of existing products and develop new ones.
A combination of physical therapy and treatment with Medtronic's spinal-cord-stimulating devices helped three men with paraplegia move their extremities and briefly stand up on their own, The Wall Street Journal reports, regaining voluntary movement years after their injuries.
California's Sequent Medical has raked in $20 million in venture cash to support its device to treat brain aneurysms, a CE marked technology on the verge of U.S. clinical trials.
The financial backer of Trivascular Technologies, Mako Surgical, Foundation Medicine and other prominent players announced that it is committing an additional $1.6 billion to a new fund for healthcare companies.
JenaValve, the venture-backed upstart in the top-heavy aortic valve space, has bagged a $10 million extension to its Series C funding round, cash that'll help it contend with the likes of Edwards Lifesciences and Medtronic on the European market.
Daktari Diagnostics achieved another milestone in its quest to raise $30 million for its groundbreaking HIV test. The company recently brought in $13 million in equity, moving it closer to realizing its original fundraising goal, the Boston Business Journal reports.
Germany's Merck KGaA signed a licensing agreement with Menlo Park, CA-based Auxogyn to sell its fertility-enhancing diagnostic test in Europe and Canada with an option to extend the agreement to other countries.
A week after swaying an FDA panel with its colorectal cancer test, Exact Sciences raised $119.7 million through a stock offering, flipping 10 million shares at $12.75 each.
Medtronic is looking to bypass some middlemen in its Turkish operation, buying a controlling stake in one of its distributors and launching a joint venture as it works to expand its share of the growing medical device market.
Roche is beefing up its point-of-care molecular diagnostics offerings, signing a deal to acquire Marlborough, MA-based IQuum for $275 million up front and up to $175 million in milestone-based payments.
Edwards Lifesciences won a CE mark for its innovative aortic valve system. European approval for the device comes at a critical moment for the company, as it attempts to strengthen its hold on foreign markets and stay a step ahead of its competition.
CyVec and its immunoassay technology got a $10 million investment shot in the arm from Minneapolis-based Bio-Techne with an additional promise to acquire the company in the future if certain conditions are met.
TriVascular Techologies is setting the terms for its planned IPO, and the California maker of stent grafts to treat abdominal aortic aneurysms aims for a fairly robust debut.
Johnson & Johnson's Ethicon arm has been ordered to pay $1.2 million in damages in a trial alleging it produced faulty vaginal mesh that was implanted into a 64-year-old woman.
Minnesota startup Holaira attracted $42 million in new financing that will back a formal human clinical trial for a lung denervation treatment that addresses chronic obstructive pulmonary disease.
RefleXion Medical raised $11.6 million in a Series A financing round for its biologically guided radiation system for cancer treatment.
Vapotherm, a maker of respiratory therapy devices, disclosed this week it finalized a $24 million round of funding from a consortium of 8 investors and expanded its board.
U.K. diagnostics developer Cytox raised nearly $2.5 million in new funding to help expand work on the development of a viable Alzheimer's biomarker.